Atripla: Difference between revisions
From Proteopedia
Jump to navigationJump to search
New page: A fixed-dose triple combination of emtricitabine, tenofovir and efavirenz (Sustiva, marketed by Bristol-Myers Squibb) was approved by the U.S. Food and Drug Administration (FDA) on Jul... |
No edit summary |
||
| Line 1: | Line 1: | ||
A fixed-dose triple combination of emtricitabine, tenofovir and [[efavirenz]] (Sustiva, marketed by Bristol-Myers Squibb) was approved by the U.S. Food and Drug Administration (FDA) on July 12, 2006, under the brand name Atripla. | A fixed-dose triple combination of [[emtricitabine]], [[tenofovir]] and [[efavirenz]] (Sustiva, marketed by Bristol-Myers Squibb) was approved by the U.S. Food and Drug Administration (FDA) on July 12, 2006, under the brand name Atripla. | ||
